My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.14 +0.59 (+0.64%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 23, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

74 75 Next >

CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial

May 02, 2024

From AstraZeneca

Via Business Wire

Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca ↗

May 01, 2024

The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic...

Via Benzinga

Topics Intellectual Property

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

May 01, 2024

From AstraZeneca

Via Business Wire

Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week ↗

April 29, 2024

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.

Via Benzinga

Topics Stocks

Should Quality-Oriented Investors Explore ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN)? ↗

April 23, 2024

Why Quality-Oriented Investors Should Consider NASDAQ:AZN.

Via Chartmill

Looking At AstraZeneca's Recent Unusual Options Activity ↗

April 19, 2024

Via Benzinga

AstraZeneca Admits Its COVID-19 Vaccine May Cause Blood Clotting Side Effect In Very Rare Case, But Causal Mechanism Unknown ↗

April 29, 2024

Discover the latest on AstraZeneca's Covid vaccine lawsuit. Allegations of serious side effects, including fatalities and brain injuries, spark legal battles. Learn about the controversy and potential...

Via Benzinga

Topics Lawsuit

Double Good News For AstraZeneca's Breast Cancer Drugs ↗

April 29, 2024

Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer.

Via Benzinga

ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow

April 29, 2024

From AstraZeneca

Via Business Wire

Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates ↗

April 28, 2024

The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for...

Via Talk Markets

Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review ↗

April 26, 2024

Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.

Via Investor's Business Daily

Top 4 Health Care Stocks That May Plunge This Month ↗

April 26, 2024

Via Benzinga

Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

April 25, 2024

Via Benzinga

AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript ↗

April 25, 2024

AZN earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday? ↗

April 25, 2024

Wall Street suffers a double blow in Thursday’s session, as softer-than-expected revenue forecasts from Meta Platforms Inc. (NASDAQ:META) are being compounded by weaker-than-expected economic growth...

Via Benzinga

Topics Economy

Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday ↗

April 25, 2024

Via Benzinga

AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance ↗

April 25, 2024

AstraZeneca reports Q1 sales of $12.68 billion, up 17% Y/Y. Despite missing adjusted EPADS, oncology sees a 26% surge, driven by Tagrisso and Imfinzi. Cardiovascular sales up 20%. R&D up 18%. Fiscal...

Via Benzinga

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market ↗

April 25, 2024

The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.

Via Investor's Business Daily

AZN Stock Earnings: AstraZeneca Misses EPS, Beats Revenue for Q1 2024 ↗

April 25, 2024

AZN stock results show that AstraZeneca missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags ↗

April 25, 2024

AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.

Via Investor's Business Daily

Q1 2024 results

April 25, 2024

From AstraZeneca

Via Business Wire

US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst ↗

April 25, 2024

The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NASDAQ:META)

Via Benzinga

3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge ↗

April 23, 2024

These are the undervalued pharmaceutical stocks to buy as they have a deep clinical pipeline which will driven earnings and cash flow growth.

Via InvestorPlace

European Stock: AstraZeneca ↗

April 22, 2024

AstraZeneca PLC is a science-led biopharmaceutical company. The company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and...

Via Talk Markets

Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges ↗

April 19, 2024

Discover the impact of Brexit on UK drug shortages. Insights from a recent Nuffield Trust study reveal a doubling in shortages since 2020. Learn about challenges in medicine supplies, regulatory...

Via Benzinga

Topics Brexit

3 Blue-Chip Stocks to Buy as High Inflation Persists ↗

April 19, 2024

These are the undervalued blue-chip stocks for inflation protection, with the Fed likely to delay the first interest rate cut.

Via InvestorPlace

Topics Economy

Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)

April 18, 2024

Via AB Newswire

Topics Economy

Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick ↗

April 17, 2024

Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300...

Via Benzinga

Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week ↗

April 21, 2024

Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.

Via Benzinga

AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows ↗

April 16, 2024

AstraZeneca's updated data from TOPAZ-1 Phase 3 trial of Imfinzi (durvalumab) in advanced biliary tract cancer patients. Unveiling long-term survival benefits and significant overall survival...

Via Benzinga

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.